Heidi Beddall
Impact in
- Infectious Diseases top 1%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
-
- Antibiotic Use and Resistance
Papers in
-
- COVID-19 Clinical Research Studies 10
-
- Maternal and fetal healthcare 1
Heidi Beddall
11 papers receiving 1.6k citations
Heidi Beddall's Hit Papers
Peers
Comparison fields: 5 of 82
- Infectious Diseases 1.3k
- Applied Microbiology and Biotechnology 35
- Internal Medicine 27
- Statistics and Probability 47
- Oncology 75
Countries citing papers authored by Heidi Beddall
This map shows the geographic impact of Heidi Beddall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heidi Beddall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heidi Beddall more than expected).
Fields of papers citing papers by Heidi Beddall
This network shows the impact of papers produced by Heidi Beddall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heidi Beddall. The network helps show where Heidi Beddall may publish in the future.
No co-authors to show.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 411 |
| 2 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 393 |
| 3 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 4 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 231 |
| 5 | 2021 | 213 | |
| 6 | Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2023 | 84 |
| 7 | 2023 | 25 | |
| 8 | 2024 | 24 | |
| 9 | 2024 | 6 | |
| 10 | 2025 | 5 | |
| 11 | 2025 | 2 | |
| 12 | 2015 | 0 |
About Heidi Beddall
Heidi Beddall is a scholar working on Infectious Diseases, Pediatrics, Perinatology and Child Health, Surgery, Nuclear Energy and Engineering and Waste Management and Disposal, having authored 12 papers that have together received 1.7k indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (10 papers), Kawasaki Disease and Coronary Complications (1 paper) and Maternal and fetal healthcare (1 paper). The work is most often cited by research in Infectious Diseases (1.3k citations), Applied Microbiology and Biotechnology (35 citations), Internal Medicine (27 citations), Statistics and Probability (47 citations) and Oncology (75 citations). Heidi Beddall has collaborated with scholars based in United Kingdom, Vietnam and Nepal. Their work appears in journals such as The Lancet, EClinicalMedicine, Nature Communications, The Lancet Infectious Diseases and The Lancet Diabetes & Endocrinology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.